|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sullivan I and Planchard D: ALK inhibitors
in non-small cell lung cancer: The latest evidence and
developments. Ther Adv Med Oncol. 8:32–47. 2016.PubMed/NCBI
|
|
3
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larsen JE, Cascone T, Gerber DE, Heymach
JV and Minna JD: Targeted therapies for lung cancer: Clinical
experience and novel agents. Cancer J. 17:512–527. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group, :
Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 25 Suppl 3:iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bordi P, Del Re M, Danesi R and Tiseo M:
Circulating DNA in diagnosis and monitoring EGFR gene mutations in
advanced non-small cell lung cancer. Transl Lung Cancer Res.
4:584–597. 2015.PubMed/NCBI
|
|
7
|
Hall RD, Le TM, Haggstrom DE and Gentzler
RD: Angiogenesis inhibition as a therapeutic strategy in non-small
cell lung cancer (NSCLC). Transl Lung Cancer Res. 4:515–523.
2015.PubMed/NCBI
|
|
8
|
Priya A, Johar K, Nair B and Wong-Riley
MT: Nuclear respiratory factor 2 regulates the transcription of
AMPA receptor subunit GluA2 (Gria2). Biochim Biophys Acta.
1843:3018–3028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Isaac JT, Ashby MC and McBain CJ: The role
of the GluR2 subunit in AMPA receptor function and synaptic
plasticity. Neuron. 54:859–871. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stepulak A, Luksch H, Gebhardt C,
Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke
KS, Turski L and Ikonomidou C: Expression of glutamate receptor
subunits in human cancers. Histochem Cell Biol. 132:435–445. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nedergaard M, Takano T and Hansen AJ:
Beyond the role of glutamate as a neurotransmitter. Nat Rev
Neurosci. 3:748–755. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu H, Takano N, Xiang L, Gilkes DM, Luo W
and Semenza GL: Hypoxia-inducible factors enhance glutamate
signaling in cancer cells. Oncotarget. 5:8853–8868. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Groot JF, Piao Y, Lu L, Fuller GN and
Yung WK: Knockdown of GluR1 expression by RNA interference inhibits
glioma proliferation. J Neurooncol. 88:121–133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi CH, Choi JJ, Park YA, Lee YY, Song
SY, Sung CO, Song T, Kim MK, Kim TJ, Lee JW, et al: Identification
of differentially expressed genes according to chemosensitivity in
advanced ovarian serous adenocarcinomas: Expression of GRIA2
predicts better survival. Br J Cancer. 107:91–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herner A, Sauliunaite D, Michalski CW,
Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H
and Kleeff J: Glutamate increases pancreatic cancer cell invasion
and migration via AMPA receptor activation and Kras-MAPK signaling.
Int J Cancer. 129:2349–2359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mcgahon AJ, Martin SJ, Bissonnette RP,
Mahboubi A, Shi Y, Mogil RJ, Nishioka WK and Green DR: The end of
the (Cell) line: Methods for the study of apoptosis in vitro.
Method Cell Biol. 46:153–185. 1995. View Article : Google Scholar
|
|
17
|
Ni B, Bai FF, Wei Y, Liu MJ, Feng ZX,
Xiong QY, Hua LZ and Shao GQ: Apoptosis induced by lipid-associated
membrane proteins from Mycoplasma hyopneumoniae in a porcine lung
epithelial cell line with the involvement of caspase 3 and the MAPK
pathway. Genet Mol Res. 14:11429–11443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He Y, Chen W, Hu Y, Luo B, Wu L, Qiao Y,
Mo Q, Xu R, Zhou Y, Ren Z, et al: E. adenophorum induces cell cycle
and apoptosis of renal cells through mitochondrial pathway and
caspase activation in Saanen Goat. PLoS One. 10:e01385042015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borges K and Dingledine R: AMPA receptors:
Molecular and functional diversity. Prog Brain Res. 116:153–170.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Henley JM and Wilkinson KA: AMPA receptor
trafficking and the mechanisms underlying synaptic plasticity and
cognitive aging. Dialogues Clin Neurosci. 15:11–27. 2013.PubMed/NCBI
|
|
21
|
Serulle Y, Arancio O and Ziff EB: A role
for cGMP-dependent protein kinase II in AMPA receptor trafficking
and synaptic plasticity. Channels. 2:230–232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Priya A, Johar K, Nair B and Wong-Riley
MT: Specificity protein 4 (Sp4) regulates the transcription of AMPA
receptor subunit GluA2 (Gria2). Biochim Biophys Acta.
1843:1196–1206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Craig AM, Blackstone CD, Huganir RL and
Banker G: The distribution of glutamate receptors in cultured rat
hippocampal neurons: Postsynaptic clustering of AMPA-selective
subunits. Neuron. 10:1055–1068. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wenthold RJ, Petralia RS, J II Blahos and
Niedzielski AS: Evidence for multiple AMPA receptor complexes in
hippocampal CA1/CA2 neurons. J Neurosci. 16:1982–1989.
1996.PubMed/NCBI
|
|
25
|
Sommer B, Köhler M, Sprengel R and Seeburg
PH: RNA editing in brain controls a determinant of ion flow in
glutamate-gated channels. Cell. 67:11–19. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ikonomidou C, Bosch F, Miksa M, Bittigau
P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L and
Olney JW: Blockade of NMDA receptors and apoptotic
neurodegeneration in the developing brain. Science. 283:70–74.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Joo JY, Kim BW, Lee JS, Park JY, Kim S,
Yun YJ, Lee SH, Lee SH, Rhim H and Son H: Activation of NMDA
receptors increases proliferation and differentiation of
hippocampal neural progenitor cells. J Cell Sci. 120:1358–1370.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoshioka A, Ikegaki N, Williams M and
Pleasure D: Expression of N-methyl-D-aspartate (NMDA) and non-NMDA
glutamate receptor genes in neuroblastoma, medulloblastoma and
other cells lines. J Neurosci Res. 46:164–178. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takeda M, Haga M, Yamada H, Kinoshita M,
Otsuka M, Tsuboi S and Moriyama Y: Ionotropic glutamate receptors
expressed in human retinoblastoma Y79 cells. Neurosci Lett.
294:97–100. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rzeski W, Ikonomidou C and Turski L:
Glutamate antagonists limit tumor growth. Biochem Pharmacol.
64:1195–1200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishiuchi S, Yoshida Y, Sugawara K, Aihara
M, Ohtani T, Watanabe T, Saito N, Tsuzuki K, Okado H, Miwa A, et
al: Ca2+-permeable AMPA receptors regulate growth of human
glioblastoma via Akt activation. J Neurosci. 27:7987–8001. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin HI, Lee YJ, Chen BF, Tsai MC, Lu JL,
Chou CJ and Jow GM: Involvement of Bcl-2 family, cytochrome c and
caspase 3 in induction of apoptosis by beauvericin in human
non-small cell lung cancer cells. Cancer Lett. 230:248–259. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Paulsen M, Ussat S, Jakob M, Scherer G,
Lepenies I, Schütze S, Kabelitz D and Adam-Klages S: Interaction
with XIAP prevents full caspase-3/−7 activation in proliferating
human T lymphocytes. Eur J Immunol. 38:1979–1987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng J, Zhang S, Wu K, Wang B, Wong JY,
Jiang H, Xu R, Ying L, Huang H, Zheng X, et al: Combined effects of
suberoylanilide hydroxamic acid and cisplatin on radiation
sensitivity and cancer cell invasion in non-small-cell lung cancer.
Mol Cancer Ther. 15:842–853. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rajagopalan P, Alahmari KA, Elbessoumy AA,
Balasubramaniam M, Suresh R, Shariff ME and Chandramoorthy HC:
Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one
(FXY-1): A novel Akt inhibitor with potent activity in lung cancer.
Cancer Chemother Pharmacol. 77:393–404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smardova J, Liskova K, Ravcukova B,
Malcikova J, Hausnerova J, Svitakova M, Hrabalkova R, Zlamalikova
L, Stano-Kozubik K, Blahakova I, et al: Complex analysis of the p53
tumor suppressor in lung carcinoma. Oncol Rep. 35:1859–1867.
2016.PubMed/NCBI
|
|
37
|
Zhang G, An Y, Lu X, Zhong H, Zhu Y, Wu Y,
Ma F, Yang J, Liu Y, Zhou Z, et al: A Novel naphthalimide compound
restores p53 function in non-small-cell lung cancer by reorganizing
the bak-Bcl-xl complex and triggering transcriptional regulation. J
Biol Chem. 291:4211–4225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iwamoto FM, Kreisl TN, Kim L, Duic JP,
Butman JA, Albert PS and Fine HA: Phase 2 trial of talampanel, a
glutamate receptor inhibitor, for adults with recurrent malignant
gliomas. Cancer. 116:1776–1782. 2010. View Article : Google Scholar : PubMed/NCBI
|
